WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Sage Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-06-06 09:54 am Sale |
2024-05-31 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 39,757 0.070% |
-6,022,239 (-99.34%) |
Filing |
| 2024-02-08 10:17 am Sale |
2023-12-29 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 6,061,996 10.100% |
-301,634 (-4.74%) |
Filing |
| 2023-07-10 08:44 am Purchase |
2023-06-30 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 6,363,630 10.650% |
847,494 (+15.36%) |
Filing |
| 2023-02-06 2:58 pm Sale |
2022-12-30 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 5,516,136 9.270% |
-1,610,275 (-22.60%) |
Filing |
| 2022-02-04 09:22 am Purchase |
2021-12-31 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 7,126,411 12.100% |
999,731 (+16.32%) |
Filing |
| 2021-08-10 07:57 am Purchase |
2021-07-30 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 6,126,680 10.480% |
1,843,051 (+43.03%) |
Filing |
| 2021-02-04 10:14 am Purchase |
2020-12-31 | 13G | Sage Therapeutics, Inc. SAGE |
WELLINGTON MANAGEMENT CO LLP | 4,283,629 8.230% |
4,283,629 (New Position) |
Filing |